We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.
- Authors
Li, Feng-fei; Gao, Gu; Li, Qian; Zhu, Hong-hong; Su, Xiao-fei; Wu, Jin-dan; Ye, Lei; Ma, Jian-hua
- Abstract
Objectives. To observe changes in blood glycemic variations and oxidative stress level before and after dapagliflozin treatment in patients with newly diagnosed T2DM. Methods. This was a randomized, double-blind, placebo-controlled, phase 3 trial. A total of 28 patients with newly diagnosed T2DM with HbA1c levels of 7.5–10.5% were randomly selected to receive dapagliflozin or placebo treatment for 24 weeks. After baseline data were collected, we analyzed glycemic variations and plasma 8-iso PGF2α level at baseline and at the endpoint. Primary outcome was the changes of mean amplitude glycemic excursion (MAGE) within groups. Results. After 24-week dapagliflozin therapy, our data showed the significant improvement of MAGE with dapagliflozin therapy (P=0.010). Compared with control group, patients in dapagliflozin group exhibited reduction in 24-hour MBG (P=0.026) and lower mean plasma glucose concentrations, especially during periods from 2400 to 0200 and 1300 to 1800 (P<0.05, resp.). In addition, plasma 8-iso PGF2α level was notably decreased in the treatment group compared to the control group (P=0.034). Conclusions. In conclusion, this study shows the ability of dapagliflozin to improve glycemic variations and associate with reduction of oxidative stress in patients with T2DM, which may benefit the cardiovascular system.
- Subjects
DAPAGLIFLOZIN; TYPE 2 diabetes diagnosis; GLYCEMIC control; OXIDATIVE stress; BLIND experiment
- Publication
Journal of Diabetes Research, 2016, p1
- ISSN
2314-6745
- Publication type
Article
- DOI
10.1155/2016/5347262